

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete If Known**

Application Number	09/875,076 10/782,596
Filing Date	June 6, 2001 02/19/2004
First Named Inventor	C. Liaw et al.
Art Unit	1846
Examiner Name	Premia Maria Mertz Ruixiang Li
Attorney Docket Number	AREN-11.US9.DIV (0239)

**(use as many sheets as necessary)**

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

3/21/2006

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete If Known**

Application Number	09/875,076 10782,596
Filing Date	June 6, 2001 02/19/2004
First Named Inventor	C. Liaw et al.
Group Art Unit	1646
Examiner Name	Prerna Maria Mertz Ruixiang Li
Attorney Docket Number	AREN-11.US9.DIV (0239)

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi		Hirsch et al., "Neuronal Vulnerability in Parkinson's Disease", <i>J Neural Transm Suppl.</i> 1997;50:79-88	
		Huiley et al., "Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons <i>In Vivo</i> ", <i>European Journal of Neuroscience</i> , Vol. 7, pp. 2431-2440, 1995	
		Berridge, Michael J., "Inositol trisphosphate and calcium signalling", <i>Nature</i> , Vol. 361, 28 January 1993	
		Wilson et al., "Orphan G-Protein-coupled receptors: the next generation of drug targets?", <i>British Journal of Pharmacology</i> (1998) 125, 1387-1392	
		Hegyi et al., "The Relationship between Protein Structure and Function: a Comprehensive Survey with Application to the Yeast Genome", <i>J. Mol. Biol.</i> (1999) 288, 147-164	
RLi		Kasuya et al., "Three-dimensional Structure Analysis of PROSITE Patterns", <i>J. Mol. Biol.</i> (1999) 288, 1673-1691	

Examiner  
Signature

Ruixiang Li

Date  
Considered

3/21/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1448A/PTO

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete If Known**

Application Number	09/875,076	10/12, 596
Filing Date	June 6, 2001	02/18/2014
First Named Inventor	Chen Liaw	
Group Art Unit	1646	
Examiner Name	P. Mertz	Rui Xiang Li
Attorney Docket Number	11.US9.DIV (AREN-0239)	

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Ruidong Li	Date Considered	3/21/2006
-----------------------	------------	--------------------	-----------

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/875,076 16/82,596
Filing Date	June 6, 2001 02/19/2004
First Named Inventor	Chen Liaw
Group Art Unit	1646
Examiner Name	P. Mertz Ruixiang Li
Attorney Docket Number	11.US9.DIV (AREN-0239)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi	BA	Standaert and Young, Treatment of Central Nervous System Degenerative Disorders, in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, Ninth Ed. (Chapter 22) pp. 503-519, 1998	
RLi	BB	Matsumoto, et al., "An Evolutionarily Conserved G-Protein Coupled receptor Family, SREB, Expressed in the Central Nervous System," Biochem. Biophys. Res. Comm. (2000) 272:578-582	
RLi	BC	Skotnick, et al., "Structural genomics and its importance for gene function analysis," Nature Biotechnol. (2000) 18:283-287	

Examiner  
Signature

Ruixiang Li

Date  
Considered

3/21/2006

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
		Applicant <b>Ruoping Chen, et al.</b> Liaw	
		Filing Date <sup>02/19/2004</sup> <b>June 6, 2001</b>	Group <b>1646</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	AA	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , 1996, 271, 1748-1755	
	AB	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK <sub>2</sub> ) receptors," <i>Am. Rev. Respir. Dis.</i> , 1992, 146(5, Pt. 1), 1177-1181	
	AC	Alexander, W.S. et al., "Point mutations within the dimer interact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578	
	AD	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349	
	AE	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , 1994, 269(16), 11687-11690	
	AF	Baxter, G., "5-HT <sub>2</sub> receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , 1995, 16, 105-110	
	AG	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene <i>v-kit</i> with the protein kinase gene family," <i>Nature</i> , 1986, 320, 415	
	AH	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G <sub>q/11</sub> by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , 1995, 270, 17741-17748	
✓	AI	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, 1998, 363-377	
RLi	AJ	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the $\alpha$ -factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925	
<b>EXAMINER</b>		Ruixiang L	<b>DATE CONSIDERED</b> 3/21/2006

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> 101783,596 <del>09/875,076</del>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Ruoping Chen, et al.</b> Liaow	
		<b>Filing Date</b> 07/19/2004 <b>June 6, 2001</b>	<b>Group</b> 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	AK	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , 1996, 51(4), 539-544	
	AL	Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," <i>J. Biol. Chem.</i> , 1996, 271(6), 2882-2885	
	AM	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G <sub>q</sub> ," <i>FEBS Lett.</i> , 1995, 363(3), 261-263	
	AN	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , 1994, 46, 121-136	
	AO	Casey, C. et al., "Constitutively active mutant 5-HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists," <i>Soc. Neurosci.</i> , 1996, Abstract #699.10	
	AP	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 7336-7340	
	AQ	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," <i>J. Biol. Chem.</i> , 1995, 270, 23398-23401	
	AR	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , 1993, 46(1), 131-134	
	AS	Chen, W. et al., "A colorimetric assay for measuring activation of G <sub>s</sub> - and G <sub>q</sub> -coupled signaling pathways," <i>Anal. Biochem.</i> , 1995, 226(2), 349-354	
y	AT	Chidiac, P. et al., "Inverse agonist activity of $\beta$ -adrenergic antagonists," <i>J. Pharm. Exp. Ther.</i> , 1994, 45, 490-499	
RLi	AU	Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," <i>J. Cardiovas. Pharmacol.</i> , 1993, 22(Suppl. 8), S377-S379	
<b>EXAMINER</b>		Ruoping Chen	<b>DATE CONSIDERED</b> 3/21/2006

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b> 10/782,596
		Applicant <b>Ruoping Chen, et al.</b> Law	
		Filing Date 02/11/2001 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	AV	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , 1996, 16(2), 5518-5526	
	AW	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , 1984, 311, 29-33	
	AX	De Dios, I. et al., "Effect of L-364,718 (CKK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , 1994, 9(2), 212-218	
	AY	Desbios-Mouthon, C. et al., "Deletion of Asn <sup>281</sup> in the $\alpha$ -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , 1996, 81(2), 719-727	
	AZ	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , 1991, 6(11), 1997-2003	
	BA	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , 1992, 7, 2549-2553	
	BB	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , 1994, 7, 396-401	
	BC	Eggericksx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , 1995, 309, 837-843	
	BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , 1992, 35, 3919-3927	
	BE	Fu, M. et al., "Functional autoimmune epitope on $\alpha_1$ -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , 1994, 344, 1660-1663	
	BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene <i>c-kit</i> in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of <i>c-kit</i> Product," <i>J. Clin. Invest.</i> , 1993, 92, 1736-1744	
RLi	BG	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), 200-206	
<b>EXAMINER</b> <i>Ruoping Chen</i>		<b>DATE CONSIDERED</b> 3/21/2006	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b> 10/782,596
		Applicant <b>Ruoping Chen, et al.</b> Lian	
		Filing Date 02/19/2004 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	BH	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , 1995, 275(2), 737-744	
	BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , 1996, 87(5), 1692-1697	
	BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel $\gamma$ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , 1995, 11(1), 76-82	
	BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , 1996, 271(4), 1857-1860	
	BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , 1984, 74, 647-651	
	BM	Herrick-Davis, K. et al., "Constitutively Active 5HT <sub>2C</sub> Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18	
	BN	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , 1995, 47, 267-270	
	BO	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , 1990, 42(1), 45-83	
	BP	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , 1995, 270(13), 7405-7410	
↓	BQ	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , 1991, 78(11), 2962-2968	
RLi	BR	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , 1992, 42, 982-990	
<b>EXAMINER</b> <i>Ruoping Chen</i>		<b>DATE CONSIDERED</b> 3/21/2006	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> <b>09/875,076</b> 10/782,596
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Ruoping Chen, et al.</b> Lian	
		<b>Filing Date</b> 02/19/2001 <b>June 6, 2001</b>	<b>Group</b> 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	<b>BS</b>	Jakubik, J. et al., "Constitutive activity of the M <sub>1</sub> -M <sub>4</sub> subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," <i>FEBS Letts.</i> , 1995, 377, 275-279	
	<b>BT</b>	Kjelsberg, M.A. et al., "Constitutive activation of the $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biol. Chem.</i> , 1992, 267(3), 1430-1433	
	<b>BU</b>	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , 1995, 9, 516-525	
	<b>BV</b>	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , 1995, 4(2), 183-188	
	<b>BW</b>	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , 1993, 7, 114-130	
	<b>BX</b>	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the <i>erbB-3</i> tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2900-2904	
	<b>BY</b>	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," <i>J. Pharm. Exp. Therap.</i> , 1996, 277(2), 840-851	
	<b>BZ</b>	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene <i>c-kit</i> Product," <i>Blood</i> , 1991, 78(11), 2834-2840	
y	<b>CA</b>	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , 1994, 271(1), 267-276	
RLi	<b>CB</b>	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," <i>J. Clin. Endocrinol. Metabl.</i> , 1995, 80(8), 2490-2494	
<b>EXAMINER</b> Ruoping Chen		<b>DATE CONSIDERED</b> 8/21/2006	

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> <b>09/875,076</b> 15782,596
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		<b>Applicant</b> <b>Ruoping Chen, et al.</b> Liao	
		<b>Filing Date</b> 02/19/2004 <b>June 6, 2001</b>	<b>Group</b> 1846 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	CC	Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , 1995, 92, 1906-1910	
	CD	Løvlie, R. et al., "The Ca <sup>2+</sup> -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet.</i> , 1996, 98, 129-133	
	CE	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , 1993, 14, 300-307	
	CF	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , 1985, 313, 144-147	
	CG	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," <i>Oncogene</i> , 1992, 7, 181-185	
	CH	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , 1996, 271(11), 6172-6178	
	CI	Lonardo, F. et al., "The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , 1990, 2(11), 992-1003	
	CJ	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , 1990, 173(3), 1169-1178	
	CK	Mann, J. et al., "Increased serotonin, and $\beta$ -adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , 1986, 43, 954-959	
	CL	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8	
RLi	CM	Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," <i>Circulation</i> , 1994, 89, 2760-2767	
<b>EXAMINER</b>		Rui Liang L.	<b>DATE CONSIDERED</b> 3/21/2006

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> <b>09/875,076-10/782,596</b>
<b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Ruoping Chen, et al.</b> Liao	
		<b>Filing Date</b> 02/19/2001 <b>June 6, 2001</b>	<b>Group</b> 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	CN	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047	
	CO	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854	
	CP	Nanevich, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , 1996, 271(2), 702-706	
	CQ	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-750	
	CR	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , 1995, 270(44), 26037-26040	
	CS	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , 1992, 263(1), 241-245	
	CT	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human $\beta_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1988, 263(31), 15985-15992	
	CU	Offermanns, S. et al., " $G_{\alpha_{15}}$ and $G_{\alpha_{16}}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , 1995, 270, 15175-15180	
	CV	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , 1994, 37, 4508-4521	
	CW	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , 1996, 271(14), 7949-7955	
RLi	CX	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metab.</i> , 1996, 81, 3584-3588	
<b>EXAMINER</b> Ruixiang Li		<b>DATE CONSIDERED</b> 3/21/2006	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b> 10/782,596
		Applicant <b>Ruoping Chen, et al.</b> Lian	
		Filing Date 02/19/2004 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLj	CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651	
	CZ	Pei, G. et al., "A constitutive active mutant $\beta_2$ -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702	
	DA	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354	
	DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , 1995, 4 (Suppl. 1), 18-28	
	DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , 1993, 45, 289-293	
	DD	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , 1991, 49, 323-328	
	DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429	
	DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and $^3\text{H}$ -acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , 1993, 25(5), 271-276	
	DG	Ren, Q. et al., "Constitutive active mutants of the $\alpha_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268, 16483-16487	
	DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active $\text{ET}_A$ receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417	
	DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , 1993, 72, 827-834	
RLi	DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , 1993, 53(22), 5355-5360	
<b>EXAMINER</b>		Rui Liang L-	<b>DATE CONSIDERED</b> 3/21/2006

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> <b>09/875,076</b> 14782,596
<b>List of Patent and Publications</b> <b>Cited by Applicant</b> <b>(Use several sheets if necessary)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Applicant</b> <b>Ruoping Chen, et al.</b> Lian	
		<b>Filing Date</b> 02/19/2004 <b>June 6, 2001</b>	<b>Group</b> 1146 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	<b>DK</b>	Samama, P. et al., "A mutation-induced activation state of the $\beta$ 2-adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268(7), 4625-4636	
	<b>DL</b>	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," <i>Am. Soc. Pharm. Exp. Ther.</i> , 1996, 50, 285-292	
	<b>DM</b>	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73, 805-811	
	<b>DN</b>	Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Rec. Signal Transduct. Res.</i> , 1997, 17(1-3), 57-73	
	<b>DO</b>	Scheer, A. et al., "The activation process of the $\alpha_{1B}$ -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 808-813	
	<b>DP</b>	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human $\alpha$ -1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," <i>J. Pharmacol.</i> , 1995, 272(1), 134-142	
	<b>DQ</b>	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5699-5703	
	<b>DR</b>	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , 1994, 15, 264-270	
	<b>DS</b>	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , 1993, 365, 441-445	
	<b>DT</b>	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin $V_{1a}$ receptors," <i>J. Clin. Invest.</i> , 1993, 92, 224-231	
RLi	<b>DU</b>	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," <i>Mol. Cell. Endocrinology</i> , 1994, 100, 115-119	
<b>EXAMINER</b>		Ruixiang Li	<b>DATE CONSIDERED</b> 3/24/2006

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b> — 10/82,596
		Applicant <b>Ruoping Chen, et al.</b> Lian	
		Filing Date 02/15/2004 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	DV	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , 1992, 80(12), 3070-3078	
	DW	Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," <i>Anal. Biochem.</i> , 1994, 223, 259-265	
	DX	Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ <i>neu</i> oncogene," <i>Science</i> , 1987, 235, 177-182	
	DY	Slamon, D. et al., "Studies of the HER-2/ <i>neu</i> proto-oncogene in human breast and ovarian cancer," <i>Science</i> , 1989, 244, 707-712	
	DZ	Solomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , 1974, 58, 541-548	
	EA	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," <i>Ann. Rev. Physiol.</i> , 1995, 58, 143-170	
	EB	ter Laak, A. et al., "Modelling and mutation studies on the histamine H <sub>1</sub> -receptor agonist binding site reveal different binding modes for H <sub>1</sub> -agonists: Asp <sup>116</sup> (TM3) has a constitutive role in receptor stimulation," <i>J. Computer-Aided Mol. Design</i> , 1995, 9, 319-330	
	EC	Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," <i>J. Biol. Chem.</i> , 1994, 269(45), 27925-27931	
	ED	Tsujimura, T. et al., "Constitutive activation of c- <i>kit</i> in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," <i>Blood</i> , 1996, 87(1), 273-283	
Y	EE	Wang, Z. et al., "Constitutive $\mu$ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," <i>Life Sci.</i> , 1994, 54(20), 339-350	
RLi	EF	Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," <i>Proc. Natl. Acad. Sci USA</i> , 1992, 89, 2140-2144	
<b>EXAMINER</b> Ruixiang Li		<b>DATE CONSIDERED</b> 3/21/2006	

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> AREN-0239	<b>Serial No.</b> 10/782, 596 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		<b>Applicant</b> Ruoping Chen, et al. Lian	
		<b>Filing Date</b> 02/19/2004 June 6, 2001—	<b>Group</b> 1646 Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	<b>EG</b>	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , 1996, 88(3), 809-816	
	<b>EH</b>	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , 1996, 15, 520-527	
	<b>EI</b>	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312	
	<b>EJ</b>	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas <i>in vitro</i> ," <i>J. Biol. Chem.</i> , 1992, 267(18), 12452-12461	
	<b>EK</b>	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , 1995, 270, 22772-22778	
	<b>EL</b>	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor ( <i>Met</i> )," <i>Oncogene</i> , 1994, 9, 1691-1697	
	<b>EM</b>	Pauwels P.J. et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Neurobiology</i> , 1998, 17, pp. 109-135.	
	<b>EN</b>	Shryock, John et al., "Inverse Agonists and Neutral Antagonists of Recombinant Human A <sub>1</sub> Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells," <i>Molecular Pharmacology</i> , 1998, 53, pp. 886-893.	
	<b>EO</b>	Wenzel-Seifert et al., "High Constitutive Activity of the Human Formyl Peptide Receptor", <i>Journal of Biological Chem.</i> , 1998, 273, pp. 24181-24189.	
V	<b>EP</b>	Forman, B.M., et al., "Androstane Metabolites Bind to and Deactivate the Nuclear Receptor CAR- $\beta$ ", <i>Nature</i> , 1998, 395, pp. 612-615.	
RLi	<b>EQ</b>	Seifert R. et al., "Different Effects of G $\alpha$ Splice Variants on $\beta_2$ -Adrenoreceptor-mediated Signaling, <i>Journal of Biological Chem.</i> , 1998, 273, pp. 5109-5116.	
<b>EXAMINER</b> Ruixiang Li		<b>DATE CONSIDERED</b> 3/21/2006	

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>AREN-0239</b>	<b>Serial No.</b> <b>09/875,076</b> 10782, 596
<b>List of Patent and Publications</b> <b>Cited by Applicant</b> <b>(Use several sheets if necessary)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Applicant</b> <b>Ruoping Chen, et al.</b> hian	
		<b>Filing Date</b> 02/19/2004 <b>June 6, 2001</b>	<b>Group</b> 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	<b>ER</b>	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 1992, XP-002145165, 183(3), 989-995	
	<b>ES</b>	Gantz, I., et al., "Molecular cloning, expression, and gene localization of a fourth melanocortin receptor," <i>J. Biol. Chem.</i> , 1993, XP-002051983, 268(20), 15174-15178	
	<b>ET</b>	Grobowski, T., et al., "Mutation of Asn <sup>111</sup> in the third transmembrane domain of the AT <sub>1a</sub> angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , 1997, XP-002145162, 272(3), 1822-1826	
	<b>EU</b>	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , 1994, XP-002145166, 203(3), 1842-1850	
	<b>EV</b>	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , 1998, XP000929737, 17(6), 493-500	
	<b>EW</b>	Noda, K., et al., "The active state of the AT <sub>1</sub> angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , 1996, XP-002145163, 35, 16435-16442	
	<b>EX</b>	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , 1996, XP-002145161, 219-2254	
	<b>EY</b>	Scheer, A., et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Receptor &amp; Signal Transduction Res.</i> , 1997, XP-000867531, 17(1-3), 57-73	
	<b>EZ</b>	Munzy D. et al., "Homo sapeins chormosome 2p13.3, clone RPCI11-433J6 - sequencing in progress - 100 unordered pieces." <i>EMBL Database Accession Number AC006087</i> , 1998.	
RLi	<b>FA</b>	Smith D.R., "Sequencing of human chromosome 10", <i>EMBL Database Accession Number AC005849</i> , 1998.	
<b>EXAMINER</b> Ruixiang Li		<b>DATE CONSIDERED</b> 3/21/2006	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. 101782, 596 <b>09/875,076</b>
		Applicant <b>Ruoping Chen, et al.</b> Liaw	
		Filing Date 02/19/2004 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	FB	O'Dowd B.F. et al., "Discovery of Three Novel G-Protein-Coupled Receptor Genes", <i>Genomics</i> , 1998, 47, pp. 310-313. (Whole document)	
	FC	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AI090920</i> , 1998. (Abstract)	
	FD	Matsuoka I. et al., "Identification of Novel members of G-protein coupled receptor subfamily", <i>Biochemical and Biophysical Research Communications</i> , 1993, 194. (whole document)	
	FE	Hillier L. et al., "Generation and analysis of 280000 human expressed sequence tags", <i>EMBL Database Accession Number H67224</i> , 1995, abstract.	
	FF	Strausberg R., "National Cancer Institute, Cancer Genome Project", <i>EMBL Database Accession Number AI131555</i> , 1998, abstract.	
	FG	Weng et al., "A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M", <i>Proceedings of the National Acad. Of Sciences of USA</i> , 1998, 95, whole document.	
	FH	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AA804531</i> , 1998, abstract.	
	FI	Stadel, et al., "Orphan G Protein-Coupled Receptors: A neglected opportunity for pioneer drug discovery", <i>Trends in Pharm. Sciences</i> , 1997, 18, pp. 430-437.	
	FJ	Williams, S., "Human DNA Sequence From close 417022 on Chromosome 6q16.1-16.3.", <i>EMBL Database Entry HS417022</i> , 1998, pp. 1-34.	
*	FK	Nichols, J.G. et al. (eds), "Indirect mechanisms of synaptic transmission", <i>From Neuron to Brain</i> , 3 <sup>rd</sup> edition, Sinauer Associates, Inc., 1992	
*	FL	Oslo et al. (Eds), <i>Remington's Pharmaceutical Sciences</i> , 16 <sup>th</sup> edition, Mack Publishing Co., 1980	
<b>EXAMINER</b> Ruoxiang Li		<b>DATE CONSIDERED</b> 3/21/2006	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b> 10/782,596
		Applicant <b>Ruoping Chen, et al.</b> Liao	
		Filing Date 02/19/2004 <b>June 6, 2001</b>	Group 1646 <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	FM	Gantz, I. et al., "Molecular cloning of a novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 268(11), pp 8246-8250	
	FN	Howard, A.D. et al., "A receptor in pituitary and hypothalamus that functions in growth hormone release", <i>Science</i> , 1996, 273, pp 974-977	
	FO	Iismaa, T.P. et al., "Isolation and chromosomal localization of a novel human G-protein-coupled receptor (GPR3) expressed predominately in the central nervous system", <i>Genomics</i> , 1994, 24, pp391-394	
	FP	Heiber, M. et al., "Isolation of three novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 26(11), pp 8246-8250	
	FQ	Bertin, B. et al., "Cellular signaling by an agonist-activated receptor/Gs-alpha fusion protein", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, pp 8827-8831	
	FR	Wise, A. et al., "Rescue of functional interactions between the alpha-2-A-adrenoreceptor and acylation-resistant forms of Gil-alpha by expressing the proteins from chimeric open reading frames", <i>J. Biol. Chem.</i> , 1997, 272, pp 24673-24678	
	FS	Burt, A.R., et al. "Agonist occupation of an alpha-2-A-adrenoreceptor-Gil-alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins", <i>J. Biol. Chem.</i> , 1997, 272, pp 10367-10375	
	FT	Jensen et al., "mRNA profiling of rat islet tumors reveals Nkx 6.1 as a Cell-specific homeodomain transcription factor", <i>J. Biol. Chem.</i> , 1996, 271(31), pp 18749-18758	
	FU	Konig et al., "Method for identifying ligands that bind to cloned Gs-orGi-coupled receptors", <i>Mol. Cell. Neuro.</i> , 1991, 2, pp331-337	
	FV	Leonard, J. et al., "The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells", <i>Proc Natl. Acad. Sci. USA</i> , 1992, 89, pp 6247-6251	
	FW	Marchese, A. et al., "Cloning of human genes encoding novel G protein-coupled receptors", <i>Genomics</i> , 1994, 23, pp 609-618	
RLi	FX	Marks, D.L. et al., "Simultaneous visualization of two cellular mRNA species in individual neurons by use of a new double in situ hybridization method", <i>Mol. &amp; Cell. Neuro.</i> , 1992, 3, pp 395-405	
EXAMINER		Ruxiang Li	DATE CONSIDERED 3/21/2006

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> AREN-0239	<b>Serial No.</b> 10/782,596 -09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		<b>Applicant</b> Ruoping Chen, et al. Lian	
		<b>Filing Date</b> 02/19/2004 June 6, 2001	<b>Group</b> 1646 Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
RLi	<b>FY</b>	O'Dowd, B. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes", <i>Gene</i> , 1997, 187, pp75-81	
	<b>FZ</b>	Sakuri, T. et al., "Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", <i>Cell</i> , 1998, 92, pp 573-585	
	<b>GA</b>	Song, Z.H., et al. "Molecular cloning and chromosomal localization of human genes encoding three closely related G-protein-coupled receptors", <i>Genomics</i> , 1995, 28, pp 347-349	
	<b>GB</b>	Suzuki, M. et al., "Regulatable promoters for use in gene therapy applications: Modification of the 5'-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low level gene expression that can be upregulated by exogenous agents that raise intracellular levels of cAMP", <i>Human Gene Therapy</i> , 1996, 7, pp 1883-1893	
	<b>GC</b>	Xu, Y. et al., "Identification of human OGR1, a novel G Protein-coupled receptor that maps to chromosome 14", <i>Genomics</i> , 1996, 35, pp 397-402	
	<b>GD</b>	Gellai, M. et al., "Nonpeptide endothelin receptor antagonists V: prevention and reversal of acute renal failure in the rat by SB 209670", <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), pp 200-206	
	<b>GE</b>	Heiber, M. et al., "Isolation of three novel human genes encoding G protein-coupled receptors", <i>DNA and Cell Biology</i> , 1995, 14(1), pp 25-35	
	<b>GF</b>	Itoh, H. et al., "Molecular cloning and sequence determination of cDNAs for subunits of the guanine nucleotide-binding proteins Gs, Gi, and G0 from rat brain", <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, pp 3776-3780	
y	<b>GG</b>	Kenakin, T., "Are receptors promiscuous? Intrinsic efficacy as a transduction phenomenon", <i>Life Sciences</i> , 1998, 43, pp 1095-1101	
RLi	<b>GH</b>	Martone, R.L. et al. "Human CRF receptor chimeras: Mapping of ligand binding determinants", 26 <sup>th</sup> meeting of the society of Neuroscience, Washington, D.C., November 16-21, 1996, Abstract No. 609.8	
<b>EXAMINER</b> Ruixiang Li		<b>DATE CONSIDERED</b> 3/1/2006	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>AREN-0239</b>		Serial No. <b>09/875,076</b> 14782,596	
				Applicant <b>Ruoping Chen, et al.</b> Liao			
				Filing Date 02/19/2004 <b>June 6, 2001</b>		Group 1646 <b>Not Yet Assigned</b>	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
RLi	GI	5,514,578	05/07/96	Hogness et al.	435	240.2	
	GJ	5,532,157	07/02/96	Fink	435	240.2	
	GK	5,573,944	11/12/96	Kirschner et al.	435	252.3	
✓	GL	5,639,616	06/17/97	Liao et al.	435	7.1	
RLi	GM	5,750,353	05/12/98	Kopin et al.	435	7.21	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GN	WO 97/11159	09/20/96	PCT	X		
	GO	WO 98/46995	10/22/98	PCT	X		
	GP	WO 99/52927	10/21/99	PCT	X		
✓	GQ	WO 98/00552	01/08/98	PCT	X		
RLi	GR	WO 98/34948	08/13/98	PCT	X		
<b>EXAMINER</b> Ruoxiang Li				<b>DATE CONSIDERED</b> 3/21/2006			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>AREN-0239</b>		Serial No. <b>09/875,076</b> 10/282,596	
				Applicant <b>Ruoping Chen, et al.</b> Lian			
				Filing Date <i>02/15/2004</i> <b>June 6, 2001</b>		Group <i>1646</i> <b>Not Yet Assigned</b>	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GS	2,135,523 CA	08/05/96	Canada	X		
	GT	WO 99 24569	05/20/99	Japan	X(abstract only)		
	GU	WO 97 21731 A	06/19/97	PCT	X		
RLi	GV	WO 98 38217 A	09/03/98	PCT	X		
<b>EXAMINER</b>				Ruixiang Li			
<b>DATE CONSIDERED</b>				3/21/2006			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>AREN-0239</b>		Serial No. <i>101782, 596</i> <del>09/875,076</del>	
				Applicant <b>Ruoping Chen, et al.</b> <i>Liam</i>			
				Filing Date <i>02/19/2004</i> <b>June 6, 2001</b>		Group <i>1646</i> <b>Not Yet Assigned</b>	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
<i>RLi</i>	<b>GW</b>	WO 00 23588	04/27/00	PCT	X		
	<b>GX</b>	WO 99 55732	04/11/99	PCT	X		
	<b>GY</b>	WO 99 46378	09/16/99	Japan	X(abstract)		
	<b>GZ</b>	WO 98 39441	09/11/98	PCT	X		
	<b>HA</b>	WO 99 24463	05/20/99	PCT	X		
	<b>HB</b>	EP 0 899 332	03/03/99	EPO	X		
	<b>HC</b>	WO 00 26369	05/11/00	PCT	X		
	<b>HD</b>	WO 99 52946	10/21/99	PCT	X		
	<b>HE</b>	WO 98 31810	07/23/98	PCT	X		
	<b>HF</b>	EP 0 860 502	08/26/98	EPO	X		
	<b>HG</b>	WO 99 25830	05/27/99	PCT	X		
	<b>HH</b>	WO 99 55734	11/04/99	PCT	X		
<i>RLi</i>	<b>HI</b>	WO 00 12707	03/09/00	PCT	X		
<b>EXAMINER</b> <i>Ruoxiang hi</i>				<b>DATE CONSIDERED</b> <i>3/21/2006</i>			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>AREN-0239</b>		Serial No. <b>09/875,076</b> 10/782, 596	
				Applicant <b>Ruoping Chen, et al.</b> Lian			
				Filing Date <b>June 6, 2001</b>		Group 1646 <b>Not Yet Assigned</b>	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Translation YES	NO	
RLi	HJ	WO 00 11170	03/02/00	PCT	X		
	HK	WO 00 11166	03/02/00	PCT	X		
	HL	WO 98 50549	11/12/98	PCT	X		
	HM	WO 00 28028	05/18/00	PCT	X		
	HN	WO 99 42484	08/26/99	PCT	X		
	HO	WO 97 20045	06/05/97	PCT	X		
	HP	WO 97 24929	07/17/97	PCT	X		
y	HQ	WO 00 11015	03/02/00	PCT	X		
RLi	HR	WO 98 46995	10/22/98	PCT	X		
<b>EXAMINER</b> Ruixiang Li				<b>DATE CONSIDERED</b> 3/24/2006			

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet 1 of 2

**Complete If Known**

<b>Application Number</b>	10/782,596
<b>Filing Date</b>	February 19, 2004
<b>First Named Inventor</b>	C.W. Liaw
<b>Art Unit</b>	Not Yet Assigned 1646
<b>Examiner Name</b>	Not Yet Assigned Ruixiang Li
<b>Attorney Docket Number</b>	11.US12.CON

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Ruxiang Li	Date Considered	3/21/2006
-----------------------	------------	--------------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10782,596
Filing Date	02/19/2004
First Named Inventor	Liao et al.
Art Unit	1646
Examiner Name	Ruxiang Li
Attorney Docket Number	

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi	A3	BENTLEY, "Genomic sequence information should be released immediately and freely to the public," The Sanger Institute, Human Genome Project Policy Forum, Science (1998) 274:533-534.	
	A4	The Sanger Institute: Data Release Policy, www.sanger.ac.uk, May 24, 2002.	
	A5	Genbank Acc. #AL035423, update version of February 12, 1999.	
	A6	Genbank Acc. #AL035423, update version of February 24, 1999.	
	A7	Genbank Acc. #AL035423, update version of February 27, 1999.	
	A8	Genbank Acc. #AL035423, update version of April 21, 1999.	
	A9	Genbank Acc. #AL035423, update version of November 23, 1999.	
RLi	A10	Sequence Revision History for Genbank Acc. #AL035423.	

Examiner  
Signature

Ruxiang Li

Date  
Considered

3/21/2006


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

\* Not in file





PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	10/782,596
Filing Date	February 19, 2004
First Named Inventor	Chen Liaw
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	AREN11.US12.CON

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi	A32	Gracheck et al., <i>Annual Rep. Med. Chem.</i> (1993) 28:161-166.	
	A33	Major et al. "Challenges of high throughput screening against cell surface receptors," <i>J. of Receptor and Signal Transduction Res.</i> (1995) 15:595-607.	
	A34	Jayawickreme et al. "Gene expression systems in the development of high-throughput screens," <i>Current Opinion in Biotechnology</i> (1997) 629-634.	
	A35	Ji et al., "G Protein-Coupled Receptors," <i>J. Biol. Chem.</i> (1998) 273:17299-17302.	
	A36	Smith et al., <i>Assays of Cycle Nucleotides: A Review of Current Techniques</i> , App. Biochem Biotechnol (1993) 41:189-218.	
RLi	A37	Murdoch et al., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> (2000) 95:3032-3043.	

Examiner Signature	Ruixiang Li	Date Considered	3/21/2006
-----------------------	-------------	--------------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

References Cited

Application No. 09/876,076 Chem Ab  
Examiner 10/202/06 Group Art Unit 1646  
Page 1 of 1

U.S. PATENT DOCUMENTS

DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
B				
C				
D				
E				
F				
G				
H				
I				
J				
K				
L				
M				

FOREIGN PATENT DOCUMENTS

* DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N					
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

* DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U <u>Skolnick et al. Nature Biotechnology Vol. 18, pages 283-287</u>	<u>3/00</u>
V <u>Chen et al. PNAS USA Vol. 97, pages 2273-2277</u>	<u>1/99</u>
W <u>Skolnick et al., structural genomics and its importance for gene function analysis. Nature Biotechnology 18: 283-287, 2000.</u>	
X <u>Ruixiang Li</u>	<u>3/21/2006</u>

BEST AVAILABLE COPY

\* A copy of this reference is not being furnished with this Office action.  
(See Manual of Patent Examining Procedure, Section 707.05(a).)